Alopurinol como coadyuvante en el tratamiento de la hipertensión arterial en pacientes adultos jóvenes

Abstract

Background: Arterial hypertension (AHT) is a prevalent issue in several Latin American countries, with a prevalence of 42.1% in rural areas and 44.8% in urban areas. This condition is associated with complications such as heart disease, kidney disease, and dementia. Hyperuricemia is increasingly recognized and investigated due to its significant influence on various pathologies, including chronic kidney disease (CKD) and hypertension (HT), among others. Elevated uric acid levels can be a precursor to AHT, metabolic disorders, and renal diseases. Hyperuricemia and high blood pressure are directly linked to uric acid levels. Objective: This study aims to determine the usefulness of allopurinol as an adjuvant in treating hypertension in young adults. Methodology: A narrative review was conducted using data obtained from scientific medical search engines, primarily PubMed, SciELO, Web of Science, and ScienceDirect. The search will be limited to the last five years, except for relevant and necessary literature using scientific medical search engines with more years of antiquity. Conclusion: Considering the mechanisms connecting hyperuricemia and hypertension, it is reasonable to consider that hypouricemic measures with allopurinol may be beneficial in reducing cardiovascular risk. Adding allopurinol as a coadjuvant treatment for hypertension could help mitigate the risks associated with this condition.